生物制药公司TG Therapeutics Inc.(TGTX)2024年第三季度业绩公布后,盘前股价遭到重挫,暴跌19%。
财报显示,TGTX第三季度营收同比大跌近50%,仅为8388万美元,远低于分析师预期的8171万美元。调整后每股收益也仅为2美分,远不及8位分析师的平均3美分预期。净利润也由去年同期的6880万美元骤降至388万美元。
业绩低于预期令投资者信心受挫,纷纷抛售股票避险,导致TGTX当日开盘便大幅低开,随后一路大跌,从28.26美元/股直线下探至24.26美元/股,下跌幅度一度超过18.66%。截至北京时间11月4日晚上22时30分,TGTX股价报收于24.26美元/股,跌幅9.81%,全日成交量达99.4万股,换手率0.64%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.